Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI

Trial ID or NCT#

NCT00537056

Status

not recruiting iconNOT RECRUITING

Purpose

To learn whether Flourine-18 Fluoro-deoxi-glucose positron emission tomography / computed tomography (F-18 FDG PET/CT) and dynamic contrast enhanced magnetic resonance imaging (DCE MRI) are better predictors of response to therapy than the current standard of care (CT or MRI).

Official Title

Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Measurable disease by RECIST criteria - Pathologic diagnosis of renal cell cancer - Advanced (stage IV) renal cell cancer - Karnofsky performance status of (KPS>70) - Consent to participate in the clinical trial
Exclusion Criteria:
  1. - Patients who cannot complete a PET/CT scan. - Pregnant women. - Healthy volunteers. - Patients participating in other research protocols will be excluded from this study. - Metallic implants (prosthesis, ICD, pacemakers), since these are contraindications for MRI.
View All Criteria
Show Less

Investigator(s)

Sanjiv Sam Gambhir, MD, PhD
Robert Herfkens
Robert Herfkens
Radiologist
Professor of Radiology (Cardiovascular Imaging), Emeritus
Sandy Srinivas
Sandy Srinivas
Medical oncologist, Urologic specialist, Genitourinary specialist
Professor of Medicine (Oncology) and, by courtesy, of Urology

Contact us to find out if this trial is right for you.

Contact

Andrew Quon
6507361369

View on ClinicalTrials.gov